Experts from Johns Hopkins and Stanford to Explain Scleroderma Symptoms and Treatment Options
SAN FRANCISCO, July 10, 2013 /PRNewswire-USNewswire/ — America’s non-profit funding leader in scleroderma research has announced two upcoming webinars providing patients and caregivers with expert information on the symptoms and management of scleroderma (systemic sclerosis)–part of a free webinar series provided by the Scleroderma Research Foundation (SRF) and made possible with support from Gilead Sciences, MedImmune and Novartis.
The SRF webinars will feature Drs. Lorinda Chung and Laura Hummers as speakers for the webinar series intended to help the scleroderma community and others to better understand this once little known, but widespread autoimmune disease.
July 12, 2013 10:30 AM PDT – Dr. Lorinda Chung, Director of the Stanford University Scleroderma Center will present “Skin Manifestations in Scleroderma,” which will focus on the causes and treatments of this often debilitating symptom.
September 17, 2013 10:00 AM PDT – Dr. Laura Hummers, Co-Director of the Johns Hopkins Scleroderma Center, will share what is new in the world of scleroderma research and patient care.
“We hear far too often that there is not enough information available to empower patients,” explains SRF Executive Director Amy Hewitt. “With the Foundation’s access to leading experts in the field, these webinars connect patients and caregivers to the people and information that will enable them to better manage their disease and all the challenges it presents for everyday life.”
Register online at www.sclerodermaRESEARCH.org.
About Scleroderma Research Foundation:
The Scleroderma Research Foundation is America’s leading nonprofit investor in scleroderma research. It was founded in San Francisco in 1987 by scleroderma patient Sharon Monsky who lost her battle to the disease in 2002. Monsky’s legacy lives on through the organization, chaired by Luke Evnin, Ph.D., a scleroderma patient and managing partner of MPM Capital, one of the world’s largest dedicated investors in life sciences.
The Foundation’s collaborative approach is empowering scientists from leading institutions to work together and develop an understanding of how scleroderma begins, how it progresses and what can be done to slow, halt or reverse the disease process.
SOURCE Scleroderma Research Foundation